Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACORN: Cefepime vs. Piperacillin-Tazobactam in Sepsis
NCT05094154Phase 4Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Nov 2021
- Primary completion
- Oct 2022
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of cefepime, piperacillin + tazobactam in sepsis, sponsored by Vanderbilt University Medical Center. Started Nov 2021; status: completed.
02
Drugs
cefepimepiperacillin + tazobactam
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT05094154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05094154.